Announcements Trials
Browse Landscape

Phase

Phase 2 35Phase 1/2 7Phase 1 7Phase 3 6Phase NA 2

Status

Recruiting 2Completed 2Terminated 1Not yet recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2NETWORK 1

Study Type

Interventional 6

Sponsor

Cancer Type

Genitourinary 6

Conditions

Carcinoma, Renal Cell 6Kidney Neoplasms 4Ovarian Neoplasms 1Neoplasms 1Kidney Diseases 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Pancreatic Ductal 1

Interventions

Sunitinib 20Nivolumab 16cabozantinib 12Sorafenib 12pembrolizumab 11pazopanib 9Ipilimumab 9Interferon-alpha 9belzutifan 8Everolimus 8lenvatinib 7Bevacizumab 7aldesleukin 6Magnetic Resonance Spectroscopy 6Axitinib 6atezolizumab 5Interferon alpha-2 4temsirolimus 3Specimen Handling 3Radiosurgery 3Nephrectomy 3Interleukin-2 3tivozanib 2durvalumab 2avelumab 2Saline Solution 2G250 monoclonal antibody 2Fluorouracil 2Chemotherapy, Adjuvant 2CTLA-4 Antigen 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 3 × Carcinoma, Renal Cell × Axitinib × Clear all
NCT05738694 2026-03-17

Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma

Sun Yat-sen University

Phase 3 Recruiting
298 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT07383441 2026-02-03

Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer

SWOG Cancer Research Network

Phase 3 Not yet recruiting
718 enrolled
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT02853331 2026-02-02

KEYNOTE-426

Merck Sharp & Dohme LLC

Phase 3 Completed
861 enrolled 24 charts 1 FDA
Genitourinary

Carcinoma, Renal Cell

NCT02684006 2025-07-30

JAVELIN Renal 101

Pfizer

Phase 3 Completed
886 enrolled 37 charts 1 FDA
Genitourinary

Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms

NCT06364631 2025-01-16

CARE1

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3 Recruiting
1,250 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT01599754 2019-09-20

ATLAS

SFJ Pharmaceuticals, Inc.

Phase 3 Terminated
724 enrolled 17 charts
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡